about
Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood.Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder.Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response.The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathwaysSerum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients.Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues.Influence of GRIK4 genetic variants on the electroconvulsive therapy response.The role of the potassium channel gene KCNK2 in major depressive disorder.Electroconvulsive Therapy in a Patient With Chronic Catatonia: Clinical Outcomes and Cerebral 18[F]Fludeoxyglucose Positron Emission Tomography Findings.The effect of childhood trauma on blood transcriptome expression in major depressive disorderIncreased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patientsTreatment-Resistant Schizophrenia: Genetic and Neuroimaging CorrelatesGenetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy responseClinical efficacy of trauma-focused psychotherapies in treatment-resistant depression (TRD) in-patients: A randomized, controlled pilot-studyInternational Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic)Childhood trauma and glucose metabolism in patients with first-episode psychosisBDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed PatientsAssociation study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients
P50
Q35058307-98725906-5F7C-41C8-8BF6-589FB1EC0FD6Q37347446-CFD4E6A9-B6F4-40D6-9343-3D7D79186E46Q38591397-D75FED4E-D936-41D8-A8CD-CB4D3A42BC6FQ40014174-AD219CF3-CD8C-46DA-ADAE-3719BC7A000AQ41282261-CA9BB001-03F6-429B-8B90-26C0478B53EEQ47880499-37CCA94D-8A63-49C9-BCCA-5CB4E7E7D52CQ47992428-B7EF9411-20C7-4BC8-8AA6-5C52EFB4390EQ48054442-68B6A545-41FD-4A73-8631-2DA9E31F7242Q48146940-0A370459-2227-4D69-9F85-5C60D4027C6DQ48650174-5894F61F-DDD4-47CF-91C6-663CB7B8FC9EQ57721460-65CA2B55-37A8-44A0-B4C1-6734873FA2D4Q58761611-FEDF4A1D-D65F-4178-A2D8-5D2273467A41Q64108690-CBB08C21-5355-429B-80C5-4617D9435904Q90339446-C87C8F1F-8D69-4881-B926-37A20F8B82DAQ91318312-E9160A47-DFCC-4086-87AD-EFBA2AA81743Q91700038-7DF247C6-1D01-4B51-BDB8-BD69A513FAE9Q92170736-DAA2C470-23AC-401F-A900-8A55FDC238D5Q93150540-6DFED2F7-7483-4F54-BD63-EA1B2300662FQ95937928-2AE564C4-3CA7-4598-ADED-E61AE31EE5A3
P50
description
researcher ORCID ID = 0000-0002-9463-7808
@en
wetenschapper
@nl
name
Alessandra Minelli
@ast
Alessandra Minelli
@en
Alessandra Minelli
@es
Alessandra Minelli
@nl
type
label
Alessandra Minelli
@ast
Alessandra Minelli
@en
Alessandra Minelli
@es
Alessandra Minelli
@nl
prefLabel
Alessandra Minelli
@ast
Alessandra Minelli
@en
Alessandra Minelli
@es
Alessandra Minelli
@nl
P31
P496
0000-0002-9463-7808